Skip to main content
. Author manuscript; available in PMC: 2009 Jan 23.
Published in final edited form as: N Engl J Med. 2000 Feb 10;342(6):381–389. doi: 10.1056/NEJM200002103420603

Figure 3.

Figure 3

Cumulative Incidence of Further Progression of Retinopathy (an Increase of at Least Three Steps from the Level at the End of the Diabetes Control and Complications Trial [DCCT]) in the Former Conventional-Therapy and Intensive-Therapy Groups.

The data are based on regression analysis adjusted for the level of retinopathy at the end of the DCCT, whether patients received therapy as primary prevention or secondary intervention, and both the duration of diabetes and the glycosylated hemoglobin value on enrollment in the DCCT. Patients who underwent scatter photocoagulation during the DCCT were excluded from the analysis (22 in the conventional-therapy group and 9 in the intensive-therapy group). Bars denote 95 percent confidence intervals.